Conditioning of cyclophosphamide-induced leukopenia in humans

Journal of Neuropsychiatry and Clinical Neurosciences

Volumn 8, Issue 2, 1996, Pages 194-201

  Giang, Daniel W ^a   Goodman, Andrew D ^a   Schiffer, Randolph B ^a   Mattson, David H ^a   Petrie, Mary ^a   Cohen, Nicholas ^a   Ader, Robert ^a  

^a UNIVERSITY OF ROCHESTER MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLOPHOSPHAMIDE; METHYLPREDNISOLONE;

ADULT; ARTICLE; CLINICAL ARTICLE; CLINICAL PROTOCOL; CLINICAL TRIAL; CONDITIONING; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; FATIGUE; FEMALE; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; LEUKOCYTE COUNT; MALE; MULTIPLE SCLEROSIS; NAUSEA; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; VOMITING;

EID: 0029981823     PISSN: 08950172     EISSN: None     Source Type: Journal    
DOI: 10.1176/jnp.8.2.194     Document Type: Article

References (24)

1. Ader R, Felton DL, Cohen N: Psychoneuroimmunology, 2nd edition. New York, Academic Press, 1991
2. Reichlin S: Neuroendocrine-immune interactions. N Engl J Med 1993; 329:1246-1253
3. Ader R, Cohen N: CNS-immune system interactions: conditioning phenomena. Behav Brain Sci 1985; 8:379-426
4. Ader R, Cohen N: Psychoneuroimmunology: conditioning and stress. Annu Rev Psychol 1993; 44:53-85
5. Ader R, Cohen N: Conditioned immunosuppression and murine systemic lupus erythematosus. Science 1982; 215:1534-1536
6. Gorczynski RM, Kennedy M, Ciampi A: Cimetidine reverses tumor growth enhancement of plasmacytoma tumors in mice demonstrating conditioned immunosuppression. J Immunol 1985; 134:4261-4266
7. Gorczynski RM: Conditioned enhancement of skin allografts. Brain Behav Immun 1990; 4:85-92
8. Grochowicz P, Schedlowski M, Husband AJ, et al: Behavioral conditioning prolongs heart allograft survival in rats. Brain Behav Immun 1991; 5:349-356
9. Suchman A, Ader R: Pharmacodynamics and drug action: classic conditioning and placebo effects in crossover studies. Clin Pharmacol Ther 1992; 52:372-377
10. Ader R: The placebo effect as a conditioned response, in Experimental Foundations of Behavioral Medicine: Conditioning Approaches, edited by Ader R, Weimer H, Baum A. Hillside, NJ, Lawrence Erlbaum, 1988, pp 247-266
11. Bovbjerg DH, Redd WH, Maier LA, et al: Anticipatory immune suppression and nausea in women receiving cyclic chemotherapy of ovarian cancer. J Consult Clin Psychol 1990; 5:153-157
12. Buske-Kirschbaum A, Kirschbaum C, Stierle H, et al: Conditioned increase of natural killer cell activity (NKCA) in humans. Psychsom Med 1992; 54:123-132
13. Olness KC, Ader R. Conditioning as an adjunct in the pharmacotherapy of lupus erythematosus: a case report. J Develop Behav Pediatr 1992; 13:124-125
14. Carter JL, Hafler DA, Dawson DM, et al: Immunosuppression with high-dose IV cyclophosphamide and ACTH in progressive multiple sclerosis: cumulative 6-year experience in 164 patients. Neurology 1988;38(suppl 2):9-14
15. Herndon RM, Rudick RA: Multiple sclerosis, in Clinical Neurology, vol 3, edited by Joynt RJ. Philadelphia, Harper and Row, 1987, pp 33-35
16. Likosky WH: Experience with cyclophosphamide in multiple sclerosis: the cons. Neurology 1988; 38(suppl 2):14-18
17. Killian IM, Brassier RB, Armstrong RM, et al: Controlled pilot trial of monthly intravenous cyclophosphamide in multiple sclerosis. Arch Neurol 1988; 45:27-30
18. Weiner HL, Mackin GA, Orav EJ, et al: Intermittent cyclophosphamide pulse therapy in progressive multiple sclerosis: final report of the Northeast Cooperative Multiple Sclerosis Treatment Group. Neurology 1993; 43:910-918
19. McCune WJ, Golbus J, Zeldes W, et al: Clinical and immunologic effects of monthly administration of intravenous cyclophosphamide in severe systemic lupus erythematosus. N Engl J Med 1988; 318:1423-1431
20. Goodman AD, Giang DW, Mattson DA, et al: Minimal toxicity associated with monthly pulses of cyclophosphamide in the treatment of chronic progressive multiple sclerosis: preliminary observations (abstract). Ann Neurol 1990; 28:245
21. Poser CM, Paty DW, Scheinberg L, et al: New diagnostic criteria for multiple sclerosis: guidelines for research protocols. Ann Neurol 1983; 13:227-231
22. The Canadian Cooperative Multiple Sclerosis Study Group: The Canadian Cooperative trial of cyclophosphamide and plasma exchange in progressive multiple sclerosis. Lancet 1991; 337:442-446
23. Knobler RL, Panitch HS, Braheny SL, et al: Systemic alpha-interferon therapy of multiple sclerosis. Neurology 1984; 34:1273-1279
24. Kurtzke JF: Further notes on disability evaluation in multiple sclerosis with scale modifications. Neurology 1965; 15:654-661